Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds. Get Real-Time ...

Dementia cases are rising, but early action, healthy habits, and focused health policies can help reduce its impact, ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

A new study finds that dementia cases are expected to double to 1 million by 2060, with African-American cases potentially ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.

Japanese drugmaker Eisai and US partner Biogen announced today that the US Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for lecanemab-irmb (US brand name ...

The study suggests that mild cognitive impairment is linked to blood vessel dysfunction in the brain’s temporal lobes. The ...

Maryland will become the 13th state to join the State Freedom Caucus Network. The network is an extension of the ...